The San Diego Union-Tribune: Crinetics raises $40 million
November 2, 2015 — Seeking to get its first drug ready for human testing, San Diego biotech Crinetics Pharmaceuticals has raised $40 million in venture capital funding. Crinetics is developing a drug to treat acromegaly, a rare endocrine disorder caused by overproduction of human growth hormone in adults. It can raise the risk of several diseases, including type 2 diabetes, cardiovascular disease, arthritis, erectile dysfunction and menstrual abnormalities. Read the full article here.